Retracted: Allogeneic Human Umbilical Cord Mesenchymal Stem Cells for the Treatment of Autism Spectrum Disorder in Children: Safety Profile and Effect on Cytokine Levels

Abstract Individuals with autism spectrum disorder (ASD) suffer from developmental disabilities that impact communication, behavior, and social interaction. Immune dysregulation and inflammation have been linked to children with ASD, the latter manifesting in serum levels of macrophage‐derived chemo...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Neil H. Riordan, Maria Luisa Hincapié, Isabela Morales, Giselle Fernández, Nicole Allen, Cindy Leu, Marialaura Madrigal, Jorge Paz Rodríguez, Nelson Novarro
Formato:	article
Lenguaje:	EN
Publicado:	Wiley 2019
Materias:	Autism Mesenchymal stem cells Umbilical cord mesenchymal stem cells Cytokines Safety Medicine (General) R5-920 Cytology QH573-671
Acceso en línea:	https://doaj.org/article/409da016358641a0b0e740828b18ea0f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:409da016358641a0b0e740828b18ea0f
record_format	dspace
spelling	oai:doaj.org-article:409da016358641a0b0e740828b18ea0f2021-11-30T19:15:37ZRetracted: Allogeneic Human Umbilical Cord Mesenchymal Stem Cells for the Treatment of Autism Spectrum Disorder in Children: Safety Profile and Effect on Cytokine Levels2157-65802157-656410.1002/sctm.19-0010https://doaj.org/article/409da016358641a0b0e740828b18ea0f2019-10-01T00:00:00Zhttps://doi.org/10.1002/sctm.19-0010https://doaj.org/toc/2157-6564https://doaj.org/toc/2157-6580Abstract Individuals with autism spectrum disorder (ASD) suffer from developmental disabilities that impact communication, behavior, and social interaction. Immune dysregulation and inflammation have been linked to children with ASD, the latter manifesting in serum levels of macrophage‐derived chemokine (MDC) and thymus, and activation‐regulated chemokine (TARC). Mesenchymal stem cells derived from umbilical cord tissue (UC‐MSCs) have immune‐modulatory and anti‐inflammatory properties, and have been safely used to treat a variety of conditions. This study investigated the safety and efficacy of UC‐MSCs administered to children diagnosed with ASD. Efficacy was evaluated with the Autism Treatment Evaluation Checklist (ATEC) and the Childhood Autism Rating Scale (CARS), and with measurements of MDC and TARC serum levels. Twenty subjects received a dose of 36 million intravenous UC‐MSCs every 12 weeks (four times over a 9‐month period), and were followed up at 3 and 12 months after treatment completion. Adverse events related to treatment were mild or moderate and short in duration. The CARS and ATEC scores of eight subjects decreased over the course of treatment, placing them in a lower ASD symptom category when compared with baseline. MDC and TARC inflammatory cytokine levels also decreased for five of these eight subjects. The mean MDC, TARC, ATEC, and CARS values attained their lowest levels 3 months after the last administration. UC‐MSC administration in children with ASD was therefore determined to be safe. Although some signals of efficacy were observed in a small group of children, possible links between inflammation levels and ASD symptoms should be further investigated. Stem Cells Translational Medicine 2019;8:1008–1016Neil H. RiordanMaria Luisa HincapiéIsabela MoralesGiselle FernándezNicole AllenCindy LeuMarialaura MadrigalJorge Paz RodríguezNelson NovarroWileyarticleAutismMesenchymal stem cellsUmbilical cord mesenchymal stem cellsCytokinesSafetyMedicine (General)R5-920CytologyQH573-671ENStem Cells Translational Medicine, Vol 8, Iss 10, Pp 1008-1016 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	Autism Mesenchymal stem cells Umbilical cord mesenchymal stem cells Cytokines Safety Medicine (General) R5-920 Cytology QH573-671
spellingShingle	Autism Mesenchymal stem cells Umbilical cord mesenchymal stem cells Cytokines Safety Medicine (General) R5-920 Cytology QH573-671 Neil H. Riordan Maria Luisa Hincapié Isabela Morales Giselle Fernández Nicole Allen Cindy Leu Marialaura Madrigal Jorge Paz Rodríguez Nelson Novarro Retracted: Allogeneic Human Umbilical Cord Mesenchymal Stem Cells for the Treatment of Autism Spectrum Disorder in Children: Safety Profile and Effect on Cytokine Levels
description	Abstract Individuals with autism spectrum disorder (ASD) suffer from developmental disabilities that impact communication, behavior, and social interaction. Immune dysregulation and inflammation have been linked to children with ASD, the latter manifesting in serum levels of macrophage‐derived chemokine (MDC) and thymus, and activation‐regulated chemokine (TARC). Mesenchymal stem cells derived from umbilical cord tissue (UC‐MSCs) have immune‐modulatory and anti‐inflammatory properties, and have been safely used to treat a variety of conditions. This study investigated the safety and efficacy of UC‐MSCs administered to children diagnosed with ASD. Efficacy was evaluated with the Autism Treatment Evaluation Checklist (ATEC) and the Childhood Autism Rating Scale (CARS), and with measurements of MDC and TARC serum levels. Twenty subjects received a dose of 36 million intravenous UC‐MSCs every 12 weeks (four times over a 9‐month period), and were followed up at 3 and 12 months after treatment completion. Adverse events related to treatment were mild or moderate and short in duration. The CARS and ATEC scores of eight subjects decreased over the course of treatment, placing them in a lower ASD symptom category when compared with baseline. MDC and TARC inflammatory cytokine levels also decreased for five of these eight subjects. The mean MDC, TARC, ATEC, and CARS values attained their lowest levels 3 months after the last administration. UC‐MSC administration in children with ASD was therefore determined to be safe. Although some signals of efficacy were observed in a small group of children, possible links between inflammation levels and ASD symptoms should be further investigated. Stem Cells Translational Medicine 2019;8:1008–1016
format	article
author	Neil H. Riordan Maria Luisa Hincapié Isabela Morales Giselle Fernández Nicole Allen Cindy Leu Marialaura Madrigal Jorge Paz Rodríguez Nelson Novarro
author_facet	Neil H. Riordan Maria Luisa Hincapié Isabela Morales Giselle Fernández Nicole Allen Cindy Leu Marialaura Madrigal Jorge Paz Rodríguez Nelson Novarro
author_sort	Neil H. Riordan
title	Retracted: Allogeneic Human Umbilical Cord Mesenchymal Stem Cells for the Treatment of Autism Spectrum Disorder in Children: Safety Profile and Effect on Cytokine Levels
title_short	Retracted: Allogeneic Human Umbilical Cord Mesenchymal Stem Cells for the Treatment of Autism Spectrum Disorder in Children: Safety Profile and Effect on Cytokine Levels
title_full	Retracted: Allogeneic Human Umbilical Cord Mesenchymal Stem Cells for the Treatment of Autism Spectrum Disorder in Children: Safety Profile and Effect on Cytokine Levels
title_fullStr	Retracted: Allogeneic Human Umbilical Cord Mesenchymal Stem Cells for the Treatment of Autism Spectrum Disorder in Children: Safety Profile and Effect on Cytokine Levels
title_full_unstemmed	Retracted: Allogeneic Human Umbilical Cord Mesenchymal Stem Cells for the Treatment of Autism Spectrum Disorder in Children: Safety Profile and Effect on Cytokine Levels
title_sort	retracted: allogeneic human umbilical cord mesenchymal stem cells for the treatment of autism spectrum disorder in children: safety profile and effect on cytokine levels
publisher	Wiley
publishDate	2019
url	https://doaj.org/article/409da016358641a0b0e740828b18ea0f
work_keys_str_mv	AT neilhriordan retractedallogeneichumanumbilicalcordmesenchymalstemcellsforthetreatmentofautismspectrumdisorderinchildrensafetyprofileandeffectoncytokinelevels AT marialuisahincapie retractedallogeneichumanumbilicalcordmesenchymalstemcellsforthetreatmentofautismspectrumdisorderinchildrensafetyprofileandeffectoncytokinelevels AT isabelamorales retractedallogeneichumanumbilicalcordmesenchymalstemcellsforthetreatmentofautismspectrumdisorderinchildrensafetyprofileandeffectoncytokinelevels AT gisellefernandez retractedallogeneichumanumbilicalcordmesenchymalstemcellsforthetreatmentofautismspectrumdisorderinchildrensafetyprofileandeffectoncytokinelevels AT nicoleallen retractedallogeneichumanumbilicalcordmesenchymalstemcellsforthetreatmentofautismspectrumdisorderinchildrensafetyprofileandeffectoncytokinelevels AT cindyleu retractedallogeneichumanumbilicalcordmesenchymalstemcellsforthetreatmentofautismspectrumdisorderinchildrensafetyprofileandeffectoncytokinelevels AT marialauramadrigal retractedallogeneichumanumbilicalcordmesenchymalstemcellsforthetreatmentofautismspectrumdisorderinchildrensafetyprofileandeffectoncytokinelevels AT jorgepazrodriguez retractedallogeneichumanumbilicalcordmesenchymalstemcellsforthetreatmentofautismspectrumdisorderinchildrensafetyprofileandeffectoncytokinelevels AT nelsonnovarro retractedallogeneichumanumbilicalcordmesenchymalstemcellsforthetreatmentofautismspectrumdisorderinchildrensafetyprofileandeffectoncytokinelevels
_version_	1718406318092451840

Retracted: Allogeneic Human Umbilical Cord Mesenchymal Stem Cells for the Treatment of Autism Spectrum Disorder in Children: Safety Profile and Effect on Cytokine Levels

Ejemplares similares